The Experts below are selected from a list of 78 Experts worldwide ranked by ideXlab platform

Maria M Murphy - One of the best experts on this subject based on the ideXlab platform.

  • comparison of low pressure versus standard pressure fixation Carpentier Edwards Bioprosthesis
    The Annals of Thoracic Surgery, 1995
    Co-Authors: Javier Fernandez, Chao Chen, Otto B Brdlik, Glenn W Laub, Maria M Murphy
    Abstract:

    Intermediate-phase clinical results of 51 low-pressure (LP) and 234 standard-pressure (SP) fixation porcine Carpentier-Edwards (CE) valves implanted between 1977 and 1991 were compared for valve-related events. Group similarities included New York Heart Association functional class, ejection fraction, and sex. Patients with SP valves were younger (mean age, 58 versus 68 years; p = 0.0001). There were 20 in-hospital deaths (8.6%) in the SP valve group and 5 (9.8%) in the LP valve group ( p = 0.79). Follow-up was 99%, with a mean of 104 months in the SP valve group versus 55 months in the SP valve group ( p = 0.0001). The actuarial survival rate was 48.2% and 22.3% at 10 and 15 years, respectively, in the SP valve group and 34.1% at 10 years in the LP valve group ( p = 0.42). Freedom from events at 5, 10, and 15 years in the SP valve group and at 5 years in the LP valve group was as follows: for late valve-related events, 86.3%, 51.4%, and 20.2%, respectively, in the SP valve group versus 85% in the LP valve group ( p = 0.44); for valve-related death, 96.4%, 93.6%, and 87.3% in the SP valve group versus 100% in the LP valve group ( p = 0.20); for structural valve failure, 96%, 68%, and 35% in the SP valve group versus 100% in the LP valve group ( p = 0.09); and for reoperation, 95%, 61%, and 30% in the SP valve group versus 92% in the LP valve group ( p = 0.82). In conclusion, this study revealed no significant statistical difference between LP and SP valves. In the LP valve group, structural valve failure/ valve-related death was not observed, perhaps indicating a more favorable result. Absolute verification of this trend awaits long-term follow-up.

  • comparison of low pressure versus standard pressure fixation Carpentier Edwards Bioprosthesis discussion
    The Annals of Thoracic Surgery, 1995
    Co-Authors: Javier Fernandez, Chao Chen, Otto B Brdlik, Glenn W Laub, Maria M Murphy, Mark S Adkins, William A Anderson, Lynn B Mcgrath, B G Barrattboyes, J F Nistal
    Abstract:

    Intermediate-phase clinical results of 51 low-pressure (LP) and 234 standard-pressure (SP) fixation porcine Carpentier-Edwards (CE) valves implanted between 1977 and 1991 were compared for valve-related events. Group similarities included New York Heart Association functional class, ejection fraction, and sex. Patients with SP valves were younger (mean age, 58 versus 68 years ; p = 0.0001). There were 20 in-hospital deaths (8.6%) in the SP valve group and 5 (9.8%) in the LP valve group (p = 0.79). Follow-up was 99%, with a mean of 104 months in the SP valve group versus 55 months in the SP valve group (p = 0.0001). The actuarial survival rate was 48.2% and 22.3% at 10 and 15 years, respectively, in the SP valve group and 34.1% at 10 years in the LP valve group (p = 0.42). Freedom from events at 5, 10, and 15 years in the SP valve group and at 5 years in the LP valve group was as follows : for late valve-related events, 86.3%, 51.4%, and 20.2%, respectively, in the SP valve group versus 85% in the LP valve group (p = 0.44) ; for valve-related death, 96.4%, 93.6%, and 87.3% in the SP valve group versus 100% in the LP valve group (p = 0.20) ; for structural valve failure, 96%, 68%, and 35% in the SP valve group versus 100% in the LP valve group (p = 0.09) ; and for reoperation, 95%, 61%, and 30% in the SP valve group versus 92% in the LP valve group (p = 0.82). In conclusion, this study revealed no significant statistical difference between LP and SP valves. In the LP valve group, structural valve failure/valve-related death was not observed, perhaps indicating a more favorable result. Absolute verification of this trend awaits long-term follow-up.

Javier Fernandez - One of the best experts on this subject based on the ideXlab platform.

  • comparison of low pressure versus standard pressure fixation Carpentier Edwards Bioprosthesis
    The Annals of Thoracic Surgery, 1995
    Co-Authors: Javier Fernandez, Chao Chen, Otto B Brdlik, Glenn W Laub, Maria M Murphy
    Abstract:

    Intermediate-phase clinical results of 51 low-pressure (LP) and 234 standard-pressure (SP) fixation porcine Carpentier-Edwards (CE) valves implanted between 1977 and 1991 were compared for valve-related events. Group similarities included New York Heart Association functional class, ejection fraction, and sex. Patients with SP valves were younger (mean age, 58 versus 68 years; p = 0.0001). There were 20 in-hospital deaths (8.6%) in the SP valve group and 5 (9.8%) in the LP valve group ( p = 0.79). Follow-up was 99%, with a mean of 104 months in the SP valve group versus 55 months in the SP valve group ( p = 0.0001). The actuarial survival rate was 48.2% and 22.3% at 10 and 15 years, respectively, in the SP valve group and 34.1% at 10 years in the LP valve group ( p = 0.42). Freedom from events at 5, 10, and 15 years in the SP valve group and at 5 years in the LP valve group was as follows: for late valve-related events, 86.3%, 51.4%, and 20.2%, respectively, in the SP valve group versus 85% in the LP valve group ( p = 0.44); for valve-related death, 96.4%, 93.6%, and 87.3% in the SP valve group versus 100% in the LP valve group ( p = 0.20); for structural valve failure, 96%, 68%, and 35% in the SP valve group versus 100% in the LP valve group ( p = 0.09); and for reoperation, 95%, 61%, and 30% in the SP valve group versus 92% in the LP valve group ( p = 0.82). In conclusion, this study revealed no significant statistical difference between LP and SP valves. In the LP valve group, structural valve failure/ valve-related death was not observed, perhaps indicating a more favorable result. Absolute verification of this trend awaits long-term follow-up.

  • comparison of low pressure versus standard pressure fixation Carpentier Edwards Bioprosthesis discussion
    The Annals of Thoracic Surgery, 1995
    Co-Authors: Javier Fernandez, Chao Chen, Otto B Brdlik, Glenn W Laub, Maria M Murphy, Mark S Adkins, William A Anderson, Lynn B Mcgrath, B G Barrattboyes, J F Nistal
    Abstract:

    Intermediate-phase clinical results of 51 low-pressure (LP) and 234 standard-pressure (SP) fixation porcine Carpentier-Edwards (CE) valves implanted between 1977 and 1991 were compared for valve-related events. Group similarities included New York Heart Association functional class, ejection fraction, and sex. Patients with SP valves were younger (mean age, 58 versus 68 years ; p = 0.0001). There were 20 in-hospital deaths (8.6%) in the SP valve group and 5 (9.8%) in the LP valve group (p = 0.79). Follow-up was 99%, with a mean of 104 months in the SP valve group versus 55 months in the SP valve group (p = 0.0001). The actuarial survival rate was 48.2% and 22.3% at 10 and 15 years, respectively, in the SP valve group and 34.1% at 10 years in the LP valve group (p = 0.42). Freedom from events at 5, 10, and 15 years in the SP valve group and at 5 years in the LP valve group was as follows : for late valve-related events, 86.3%, 51.4%, and 20.2%, respectively, in the SP valve group versus 85% in the LP valve group (p = 0.44) ; for valve-related death, 96.4%, 93.6%, and 87.3% in the SP valve group versus 100% in the LP valve group (p = 0.20) ; for structural valve failure, 96%, 68%, and 35% in the SP valve group versus 100% in the LP valve group (p = 0.09) ; and for reoperation, 95%, 61%, and 30% in the SP valve group versus 92% in the LP valve group (p = 0.82). In conclusion, this study revealed no significant statistical difference between LP and SP valves. In the LP valve group, structural valve failure/valve-related death was not observed, perhaps indicating a more favorable result. Absolute verification of this trend awaits long-term follow-up.

A Carpentier - One of the best experts on this subject based on the ideXlab platform.

  • Carpentier Edwards pericardial Bioprosthesis in aortic position long term follow up 1980 to 1994
    The Annals of Thoracic Surgery, 1995
    Co-Authors: Michel Pellerin, J Relland, S Mihaileanu, Jean Paul Couetil, Alain Deloche, Jeannoel Fabiani, Amina Jindani, A Carpentier
    Abstract:

    Aortic valve replacement with Carpentier-Edwards pericardial Bioprosthesis was associated with excellent midterm clinical results. Long-term evaluation, however, remained to be determined. We reviewed the first 124 patients who underwent aortic valve replacement with a Carpentier-Edwards Bioprosthesis at the Hopital Broussais between 1980 and 1985. There were 67 males (54%) and 57 females (46%). The mean age at operation was 65 years (range, 18–83 years). The operative mortality (30 days) was 4%. All but 2 patients were followed up for an average of 7.7 years and a total of 973 patient years. There were 45 late deaths (4.7%/patient-year) of which 16 were valve-related (1.7%/patient-year). The actuarial survival rate was 49.9% at 12 years. The actuarial rate for freedom from valve-related mortality was 78.3% at 12 years. There were 7 thromboembolic events in 5 patients and 3 anticoagulation related hemorrhages. Freedom from structural valve deterioration was 100% at 12 years and 83.3% at 13 years. We conclude that implantation of Carpentier Edwards pericardial Bioprosthesis in aortic position is associated with an excellent long-term clinical outcome. It is believed that the improved results of this valve result from the following original features: fully flexible stent, distensible struts, infrastent tissue mounting, optimal tissue orientation, and improved preservation.

  • Carpentier Edwards pericardial Bioprosthesis in aortic position long term follow up 1980 to 1994 discussion
    The Annals of Thoracic Surgery, 1995
    Co-Authors: Michel Pellerin, J Relland, S Mihaileanu, Jean Paul Couetil, Alain Deloche, Jeannoel Fabiani, Amina Jindani, A Carpentier, W W Angell, G Stalpaert
    Abstract:

    Aortic valve replacement with Carpentier-Edwards pericardial Bioprosthesis was associated with excellent midterm clinical results. Long-term evaluation, however, remained to be determined. We reviewed the first 124 patients who underwent aortic valve replacement with a Carpentier-Edwards Bioprosthesis at the Hopital Broussais between 1980 and 1985. There were 67 males (54%) and 57 females (46%). The mean age at operation was 65 years (range, 18-83 years). The operative mortality (30 days) was 4%. All but 2 patients were followed up for an average of 7.7 years and a total of 973 patient years. There were 45 late deaths (4.7%/patient-year) of which 16 were valve-related (1.7%/patient-year). The actuarial survival rate was 49.9% at 12 years. The actuarial rate for freedom from valve-related mortality was 78.3% at 12 years. There were 7 thromboembolic events in 5 patients and 3 anticoagulation-related hemorrhages. Freedom from structural valve deterioration was 100% at 12 years and 83.3% at 13 years. We conclude that implantation of Carpentier-Edwards pericardial Bioprosthesis in aortic position is associated with an excellent long-term clinical outcome. It is believed that the improved results of this valve result from the following original features : fully flexible stent, distensible struts, infrastent tissue mounting, optimal tissue orientation, and improved preservation.

Michel Pellerin - One of the best experts on this subject based on the ideXlab platform.

  • Carpentier Edwards pericardial Bioprosthesis in aortic position long term follow up 1980 to 1994
    The Annals of Thoracic Surgery, 1995
    Co-Authors: Michel Pellerin, J Relland, S Mihaileanu, Jean Paul Couetil, Alain Deloche, Jeannoel Fabiani, Amina Jindani, A Carpentier
    Abstract:

    Aortic valve replacement with Carpentier-Edwards pericardial Bioprosthesis was associated with excellent midterm clinical results. Long-term evaluation, however, remained to be determined. We reviewed the first 124 patients who underwent aortic valve replacement with a Carpentier-Edwards Bioprosthesis at the Hopital Broussais between 1980 and 1985. There were 67 males (54%) and 57 females (46%). The mean age at operation was 65 years (range, 18–83 years). The operative mortality (30 days) was 4%. All but 2 patients were followed up for an average of 7.7 years and a total of 973 patient years. There were 45 late deaths (4.7%/patient-year) of which 16 were valve-related (1.7%/patient-year). The actuarial survival rate was 49.9% at 12 years. The actuarial rate for freedom from valve-related mortality was 78.3% at 12 years. There were 7 thromboembolic events in 5 patients and 3 anticoagulation related hemorrhages. Freedom from structural valve deterioration was 100% at 12 years and 83.3% at 13 years. We conclude that implantation of Carpentier Edwards pericardial Bioprosthesis in aortic position is associated with an excellent long-term clinical outcome. It is believed that the improved results of this valve result from the following original features: fully flexible stent, distensible struts, infrastent tissue mounting, optimal tissue orientation, and improved preservation.

  • Carpentier Edwards pericardial Bioprosthesis in aortic position long term follow up 1980 to 1994 discussion
    The Annals of Thoracic Surgery, 1995
    Co-Authors: Michel Pellerin, J Relland, S Mihaileanu, Jean Paul Couetil, Alain Deloche, Jeannoel Fabiani, Amina Jindani, A Carpentier, W W Angell, G Stalpaert
    Abstract:

    Aortic valve replacement with Carpentier-Edwards pericardial Bioprosthesis was associated with excellent midterm clinical results. Long-term evaluation, however, remained to be determined. We reviewed the first 124 patients who underwent aortic valve replacement with a Carpentier-Edwards Bioprosthesis at the Hopital Broussais between 1980 and 1985. There were 67 males (54%) and 57 females (46%). The mean age at operation was 65 years (range, 18-83 years). The operative mortality (30 days) was 4%. All but 2 patients were followed up for an average of 7.7 years and a total of 973 patient years. There were 45 late deaths (4.7%/patient-year) of which 16 were valve-related (1.7%/patient-year). The actuarial survival rate was 49.9% at 12 years. The actuarial rate for freedom from valve-related mortality was 78.3% at 12 years. There were 7 thromboembolic events in 5 patients and 3 anticoagulation-related hemorrhages. Freedom from structural valve deterioration was 100% at 12 years and 83.3% at 13 years. We conclude that implantation of Carpentier-Edwards pericardial Bioprosthesis in aortic position is associated with an excellent long-term clinical outcome. It is believed that the improved results of this valve result from the following original features : fully flexible stent, distensible struts, infrastent tissue mounting, optimal tissue orientation, and improved preservation.

Mohamed Soliman A Hamad - One of the best experts on this subject based on the ideXlab platform.

  • mid term haemodynamic and clinical results after aortic valve replacement using the freedom solo stentless Bioprosthesis versus the Carpentier Edwards perimount stented Bioprosthesis
    European Journal of Cardio-Thoracic Surgery, 2016
    Co-Authors: Ellen P J Van Der Straaten, Leonard M Rademakers, Albert H M Van Straten, Saskia Houterman, Mohamed Soliman A Hamad
    Abstract:

    OBJECTIVES: The aim of this study was to investigate the mid-term haemodynamic and clinical results after aortic valve replacement (AVR) using the Sorin Freedom Solo (SFS) stentless Bioprosthesis, compared with the standard Carpentier Edwards Perimount (CEP) stented Bioprosthesis. METHODS: In this retrospective cohort study of prospectively collected data, 116 patients were included in the SFS group (53 males; median age 74 years, range 56-85 years), and 122 patients in the CEP group (85 males; median age 73 years, range 43-88 years) between July 2007 and January 2013. Echocardiography was performed at 6 weeks after surgery in our centre, and the most recent echocardiography (in our centre or in referring cardiology departments) was requested. Between September 2013 and April 2014, all patients were called by the same researcher to gain clinical follow-up data. RESULTS: Mid-term mortality was 16.4% in the SFS group (19 patients) and 21.3% in the CEP group (26 patients); (P = 0.3). The mean transvalvular gradient was 7.4 ± 3.1 mmHg in the SFS group, and 11.6 ± 3.2 mmHg in the CEP group at 6 weeks postoperatively (P < 0.001). When stratified by labelled valve size, mean gradients were significantly lower in the SFS group for every size (P ≤ 0.03). After 3.3 ± 1.4 years of follow-up, the mean gradient was still significantly lower in the SFS group than that in the CEP group (P < 0.001). Clinical follow-up showed relatively low complication rates. CONCLUSION: These data suggest that the Sorin Freedom Solo stentless Bioprosthesis is as safe as the Carpentier Edwards Bioprosthesis, and provides better short- and mid-term haemodynamic performance than the Carpentier Edwards Bioprosthesis.